Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of a Selective AKT1 E17K Allosteric Inhibitor, ATV-1601, in Patients With Advanced Solid Tumors

NCT07038369 is registered in ClinicalTrials.gov with Atavistik Bio, Inc as lead sponsor.

NCT NCT07038369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07038369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of a Selective AKT1 E17K Allosteric Inhibitor, ATV-1601, in Patients With Advanced Solid Tumors
Lead sponsor
Atavistik Bio, Inc
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 29, 2025
Completion date
January 31, 2029
Enrollment
134 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, breast cancer, breast carcinoma, breast diseases, breast neoplasms, cervical cancers, cervical carcinoma, cervical neoplasms, endometrial cancer, endometrial carcinoma (ec), endometrial neoplasm, er positive breast cancer, fallopian cancer, genital neoplasms, female, gynecologic cancers, gynecologic neoplasm, neoplasms, neoplasms by site, ovarian cancer, ovarian carcinoma, ovarian neoplasms, prostate cancers, prostate carcinoma, solid tumors, triple negative breast cancer, urogenital neoplasms, uterine neoplasms